<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564018</url>
  </required_header>
  <id_info>
    <org_study_id>UTSW-052006-056</org_study_id>
    <secondary_id>816</secondary_id>
    <nct_id>NCT00564018</nct_id>
  </id_info>
  <brief_title>Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH</brief_title>
  <official_title>Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether using a long-acting insulin analog at the time of diagnosis, instead of
      intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin
      in children with newly diagnosed type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Type 1 diabetes (or insulin dependent diabetes mellitus (IDDM)) is a very common
      disorder affecting 1/400 persons by the age of 18 years and over 1 million people in the
      United States alone. An autoimmune disorder affecting the endocrine pancreas, it causes, in
      the untreated state, high blood glucose levels and ketosis. Over longer periods of time it
      can contribute to growth failure, malnutrition, and even death. It is responsible for a
      disproportionate percentage of the diabetes associated retinopathy and nephropathy seen in
      adults with diabetes (although type 1 diabetes only accounts for a small percentage of the
      total populace of patients with diabetes). Although insulin allows most children with this
      disease to grow and develop normally, it will not provide a permanent cure.

      Many techniques have been studied to attempt to prevent the onset or progression of the
      autoimmune destruction of islets associated with type 1 diabetes, including a variety of
      immunomodulatory drugs, nicotinamide and small doses of insulin itself. Thus far nothing has
      proven completely successful. Some investigators have suggested that intensive control early
      in the disease process will slow the progression of the disease, but these results remain
      controversial. Ultimately, any treatment aimed at the prevention or cure of diabetes must
      have as its goal the preservation of the insulin secretory capacity of the pancreas.

      In recent years, a number of insulin analogs have been developed which have different
      time-action profiles in humans. Currently, all children diagnosed with type 1 diabetes are
      placed on a combination of a long-acting insulin (such as insulins detemir or glargine) or a
      moderate-acting insulin (such as NPH), and a short acting insulin (such as lispro, aspart or
      regular insulin) as soon as they demonstrate they are able to resume a regular diet after
      their initial presentation. Each of the long- and moderate-acting insulins are given once or
      twice daily and the short-acting insulins at least twice and up to 4-5 times daily.

      Normally, the pancreas secretes a basal level of insulin at rest, and then when challenged
      with a carbohydrate load, responds with an acute surge of insulin release. Intuitively, one
      might surmise that a pharmaceutical preparation that more closely mimics the normal
      physiological profile of the pancreas might be beneficial over the long term to pancreatic
      beta cell function. Levemir (insulin detemir) and Lantus (insulin glargine) are two
      relatively new insulin analogs known for their consistent and reproducible absorption
      profiles and steady time-action profiles. In comparison, insulin NPH is a product that had
      been the standard of care for children with diabetes for many years until the availability of
      the newer analogs, but is characterized by a peaking profile (with onset of action 2-4 hours
      after injection and peak effect 8-10 hours after injection). The combination of an insulin
      which mimics the basal insulin production of a pancreas at rest (i.e., glargine or detemir),
      together with a short-acting insulin with meals which mimics the bolus production of insulin
      generated in response to a carbohydrate load (regular, lispro or aspart), might allow for
      smoother blood glucose trends when compared to a combination of two &quot;peaking&quot; insulins (such
      as NPH and aspart).

      In addition to the therapeutic benefit of better blood glucose control, we hypothesize that
      the maintenance of a steady baseline level of insulin with use of the newer insulin analogs
      may contribute to a longer period of pancreatic rest in the child newly diagnosed with
      diabetes. Many children with diabetes enter what is known as a &quot;honeymoon phase&quot; shortly
      after their diagnosis, which is characterized by relative ease of blood glucose control and
      relatively lower insulin requirements. This period represents a time during which the body is
      still able to make some insulin on its own.

      We have retrospective data to suggest that children started on insulin glargine at diagnosis
      do, in fact, achieve significantly better glycemic control than age-matched children started
      on insulin NPH. This was assessed by HgbA1c measurements, which averaged a full percentage
      point lower at their 9 month visit for the glargine treated patients (Figure 1). A failure to
      see a significant improvement in patients switched from NPH to glargine well after diagnosis
      suggests that there is something to the initiation of treatment with glargine: perhaps the
      reason for improved control is a prolonged honeymoon period, in which the preservation of a
      small amount of innate insulin production allows for easier disease management.

      What effect, if any, our current treatment modalities - specifically the choice of the longer
      acting insulin - have on the preservation of innate insulin secretory capacity remains
      unknown. If treatments aimed at the prevention or cure of diabetes are to maximize this
      secretory capacity, optimizing the insulin regimen may be imperative, and lack of attention
      to this parameter may confound trials of other interventions.

      CONCISE SUMMARY OF PROJECT: Children aged 6-18 years who have been diagnosed with type 1
      diabetes within the past 2 weeks will be randomized and placed in one of three treatment
      groups. 24 children will be randomized to each of three treatment arms differentiated by the
      choice of the longer-acting insulin (i.e. either detemir, glargine or NPH). All children will
      be treated with insulin aspart as the short-acting insulin to be used in combination with
      their longer-acting insulin. The insulin secretory capacity of the pancreas will be measured
      and compared between the groups by measuring C-peptide levels following a mixed meal
      tolerance test (using Boost) at 1, 6 and 12 months after diagnosis. Current standard of care
      as practiced at our institution is for these children to be seen every 3 months by a
      physician or advanced practice nurse at Children's Medical Center, Dallas. At each of these
      visits the children will have HgbA1c values measured and total daily insulin doses recorded.
      These will be secondary outcome measures for the purpose of this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Presumed loss of clinical equipoise between the agents being investigated
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide Area Under the Curve</measure>
    <time_frame>Although measured at 1, 6 and 12 months, the primary outcomes was a comparison between treatment groups at 6 months after diagnosis</time_frame>
    <description>We measured the insulin secretory capacity of the pancreas by measuring C-peptide levels (and calculating the C-peptide area under the curve (AUC) using the trapezoidal method following a mixed meal tolerance test (using Boost) at 1, 6 and 12 months after diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis</measure>
    <time_frame>6 months</time_frame>
    <description>We assessed glycemic control via measurement of Hemoglobin A1c at each quarterly clinic visit after diagnosis of diabetes. Data on the 6 month time point are presented</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Detemir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin detemir</intervention_name>
    <description>Dosage adjusted to meet age-specific glycemic goals throughout course of study.</description>
    <arm_group_label>Detemir</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.</description>
    <arm_group_label>Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH</intervention_name>
    <description>Dosage to be adjusted to meet age specific glycemic goals throughout course of study.</description>
    <arm_group_label>NPH</arm_group_label>
    <other_name>Neutral Protamine Hagedorn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type 1 diabetes within 1 week of diagnosis

          -  Age 6 - 18 years

          -  Care provided at Children's Medical Center, Dallas

        Exclusion Criteria:

          -  Actual treatment with oral drugs influencing beta cell function or blood glucose
             levels (e.g. oral hypoglycemic agents)

          -  Actual treatment with drugs influencing insulin sensitivity (e.g. Metformin, or
             systemic steroids)

          -  Significant concomitant disease likely to interfere with glucose metabolism (children
             with active bacterial infections at the time of diagnosis must be cured prior to
             entry)

          -  Expected poor compliance

          -  Pregnancy

          -  Any other condition that by the judgement of the investigator may be potentially
             harmful to the patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soumya Adhikari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <results_first_submitted>March 21, 2019</results_first_submitted>
  <results_first_submitted_qc>October 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2019</results_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes, basal-bolus, honeymoon, C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Detemir</title>
          <description>Subjects randomized to treatment with insulins detemir and aspart</description>
        </group>
        <group group_id="P2">
          <title>NPH Insulin</title>
          <description>Subjects randomized to treatment with insulins NPH and aspart</description>
        </group>
        <group group_id="P3">
          <title>Glargine</title>
          <description>Subjects randomized to treatment with insulins glargine and aspart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who completed randomization into one of the three treatment arms</population>
      <group_list>
        <group group_id="B1">
          <title>Detemir</title>
          <description>Subjects randomized to treatment with insulins detemir and aspart</description>
        </group>
        <group group_id="B2">
          <title>Isophane (NPH) Insulin</title>
          <description>Subjects randomized to treatment with insulins NPH and aspart</description>
        </group>
        <group group_id="B3">
          <title>Glargine</title>
          <description>Subjects randomized to treatment with insulins glargine and aspart</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Subjects were recruited immediately after diagnosis of diabetes. Subjects who then tested (-) for type 1 diabetes associated antibodies were excluded from further analyses.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1" spread="3.0"/>
                    <measurement group_id="B2" value="11.0" spread="1.6"/>
                    <measurement group_id="B3" value="9.9" spread="2.5"/>
                    <measurement group_id="B4" value="10.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (percent)</title>
          <population>Subjects were enrolled immediately after diagnosis of diabetes. Subjects who then were antibody (-) for type 1 diabetes associated antibodies are excluded from the baseline data reported.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="1.7"/>
                    <measurement group_id="B2" value="12.6" spread="1.7"/>
                    <measurement group_id="B3" value="12.1" spread="1.8"/>
                    <measurement group_id="B4" value="12.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bicarbonate (HCO3) (meq/L)</title>
          <population>Subjects were recruited immediately after diagnosis of diabetes. Subjects who then tested (-) for type 1 diabetes associated antibodies were excluded from further analyses.</population>
          <units>meQ/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="4.7"/>
                    <measurement group_id="B2" value="15.6" spread="6.1"/>
                    <measurement group_id="B3" value="14.9" spread="8.1"/>
                    <measurement group_id="B4" value="17.3" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta Hydroxy Butyrate (mmol/L)</title>
          <population>Subjects were recruited immediately after diagnosis of diabetes. Subjects who then tested (-) for type 1 diabetes associated antibodies were excluded from further analyses.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="2.6"/>
                    <measurement group_id="B2" value="3.9" spread="3.5"/>
                    <measurement group_id="B3" value="7.9" spread="4.0"/>
                    <measurement group_id="B4" value="5.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Daily Dose of Insulin (Units/kg/day)</title>
          <population>Subjects were recruited immediately after diagnosis of diabetes. Subjects who then tested (-) for type 1 diabetes associated antibodies were excluded from further analyses.</population>
          <units>Units/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.70" spread="0.11"/>
                    <measurement group_id="B2" value="0.69" spread="0.12"/>
                    <measurement group_id="B3" value="0.75" spread="0.14"/>
                    <measurement group_id="B4" value="0.70" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C-peptide Area Under the Curve</title>
        <description>We measured the insulin secretory capacity of the pancreas by measuring C-peptide levels (and calculating the C-peptide area under the curve (AUC) using the trapezoidal method following a mixed meal tolerance test (using Boost) at 1, 6 and 12 months after diagnosis.</description>
        <time_frame>Although measured at 1, 6 and 12 months, the primary outcomes was a comparison between treatment groups at 6 months after diagnosis</time_frame>
        <population>All subjects who completed 6 month mixed meal tolerance test (MMTT)s</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Subjects randomized to treatment with insulins detemir and aspart</description>
          </group>
          <group group_id="O2">
            <title>NPH Insulin</title>
            <description>Subjects randomized to treatment with insulins NPH and aspart</description>
          </group>
          <group group_id="O3">
            <title>Glargine</title>
            <description>Subjects randomized to treatment with insulins glargine and aspart</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide Area Under the Curve</title>
          <description>We measured the insulin secretory capacity of the pancreas by measuring C-peptide levels (and calculating the C-peptide area under the curve (AUC) using the trapezoidal method following a mixed meal tolerance test (using Boost) at 1, 6 and 12 months after diagnosis.</description>
          <population>All subjects who completed 6 month mixed meal tolerance test (MMTT)s</population>
          <units>ng*hr/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" lower_limit="143" upper_limit="312"/>
                    <measurement group_id="O2" value="144" lower_limit="83" upper_limit="302"/>
                    <measurement group_id="O3" value="51" lower_limit="29" upper_limit="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis</title>
        <description>We assessed glycemic control via measurement of Hemoglobin A1c at each quarterly clinic visit after diagnosis of diabetes. Data on the 6 month time point are presented</description>
        <time_frame>6 months</time_frame>
        <population>Data is presented for each subject at each time for which there was a measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Subjects randomized to treatment with insulins detemir and aspart</description>
          </group>
          <group group_id="O2">
            <title>NPH Insulin</title>
            <description>Subjects randomized to treatment with insulins NPH and aspart</description>
          </group>
          <group group_id="O3">
            <title>Glargine</title>
            <description>Subjects randomized to treatment with insulins glargine and aspart</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis</title>
          <description>We assessed glycemic control via measurement of Hemoglobin A1c at each quarterly clinic visit after diagnosis of diabetes. Data on the 6 month time point are presented</description>
          <population>Data is presented for each subject at each time for which there was a measure.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="1.3"/>
                    <measurement group_id="O2" value="8.0" spread="2.0"/>
                    <measurement group_id="O3" value="7.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Detemir</title>
          <description>Subjects randomized to treatment with insulins detemir and aspart</description>
        </group>
        <group group_id="E2">
          <title>NPH Insulin</title>
          <description>Subjects randomized to treatment with insulins NPH and aspart</description>
        </group>
        <group group_id="E3">
          <title>Glargine</title>
          <description>Subjects randomized to treatment with insulins glargine and aspart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Interpretation of the data is limited by the small sample sizes due to early study termination</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Soumya Adhikari, MD</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214 456 5959</phone>
      <email>soumya.adhikari@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

